-0.61%
-2.78%
-25.98%
-36.62%
-28.83%
12.24%
103.19%
AI Spotlight on REGN
Company Description
Regeneron Pharmaceuticals, Inc.discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Market Data
| Last Price | 683.08 |
| Change Percentage | -0.61% |
| Open | 688.31 |
| Previous Close | 687.27 |
| Market Cap ( Millions) | 73822 |
| Volume | 771103 |
| Year High | 1211.2 |
| Year Low | 666.25 |
| M A 50 | 727.19 |
| M A 200 | 950.53 |
Financial Ratios
| FCF Yield | 4.58% |
| Dividend Yield | 0.00% |
| ROE | 16.85% |
| Debt / Equity | 9.22% |
| Net Debt / EBIDTA | 14.33% |
| Price To Book | 2.52 |
| Price Earnings Ratio | 15.86 |
| Price To FCF | 21.86 |
| Price To sales | 5.33 |
| EV / EBITDA | 15.42 |
News
- Jan -30 - Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join – Contact Levi & Korsinsky
- Jan -30 - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
- Jan -30 - REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- Jan -30 - The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
- Jan -30 - testREGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Jan -30 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
- Jan -29 - Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman
- Jan -29 - ROSEN, A TOP-RANKED LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
- Jan -29 - The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline
- Jan -29 - REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
- Jan -29 - Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
- Jan -29 - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
- Jan -29 - REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- Jan -29 - REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Jan -29 - Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- Jan -29 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
- Jan -29 - ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
- Jan -29 - REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Jan -28 - REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Jan -28 - Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report - Hagens Berman
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medicines
Expected Growth : 7.0 %
What the company do ?
Regeneron Pharmaceuticals, Inc. develops innovative medicines for eye diseases, cancer, and rare genetic disorders, including Eylea, Dupixent, and Libtayo.
Why we expect these perspectives ?
Regeneron Pharmaceuticals, Inc.'s 7.0% growth in medicines is driven by increasing demand for Eylea in diabetic retinopathy and wet age-related macular degeneration, strong sales of Dupixent in atopic dermatitis and asthma, and growing adoption of Libtayo in cutaneous squamous cell carcinoma, as well as a strong pipeline of innovative therapies.
Regeneron Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| EYLEA | A vascular endothelial growth factor (VEGF) inhibitor used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. |
| Dupixent | A monoclonal antibody that inhibits the action of interleukin-4 and interleukin-13, used to treat moderate-to-severe atopic dermatitis and asthma. |
| Praluent | A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used to treat high cholesterol. |
| Libtayo | A programmed death receptor-1 (PD-1) inhibitor used to treat cutaneous squamous cell carcinoma. |
| Inmazeb | A monoclonal antibody used to treat Zaire ebolavirus infection. |
| Evkeeza | A monoclonal antibody used to treat homozygous familial hypercholesterolemia. |
Regeneron Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Regeneron Pharmaceuticals, Inc. has a low threat of substitutes due to its unique biotechnology products and strong research and development capabilities.
Bargaining Power Of Customers
Regeneron Pharmaceuticals, Inc. has a medium bargaining power of customers due to the presence of a large number of customers, but the company's strong brand reputation and product offerings mitigate this power.
Bargaining Power Of Suppliers
Regeneron Pharmaceuticals, Inc. has a low bargaining power of suppliers due to its strong relationships with suppliers and its ability to negotiate favorable terms.
Threat Of New Entrants
Regeneron Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for biotechnology products and the increasing number of new entrants in the market.
Intensity Of Rivalry
Regeneron Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 9.43% |
| Debt Cost | 3.95% |
| Equity Weight | 90.57% |
| Equity Cost | 4.78% |
| WACC | 4.70% |
| Leverage | 10.41% |
Regeneron Pharmaceuticals, Inc. : Quality Control
Regeneron Pharmaceuticals, Inc. passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who … |
| INVA | Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| MCK | McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment … |
| MRNA | Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AbbVie
A-Score
1-Year Total Return ->
🥈
Innoviva
A-Score
1-Year Total Return ->
🥉
Vertex Pharmaceuticals
A-Score
1-Year Total Return ->
4
McKesson
A-Score
1-Year Total Return ->
5
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
6
